Company profile
Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MIN-117 | phase2 | — | 1 | no active trials |
| ROLUPERIDONE HYDROCHLORIDE | phase1 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03072056 | phase1 | completed | 2017-01-09 | 2017-07-07 | Minerva Neurosciences | A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers |
| NCT03038646 | phase1 | completed | 2016-11-30 | 2017-04-20 | Minerva Neurosciences | A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects |
| NCT03446846 | phase2 | completed | 2018-03-30 | 2019-11-21 | Minerva Neurosciences | A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder |
| NCT06107803 | phase1 | completed | 2023-10-13 | 2024-01-12 | Minerva Neurosciences | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia |
| NCT02232529 | phase1 | completed | 2014-09-01 | 2015-02-01 | Minerva Neurosciences | Pharmacokinetic Study of MIN-101 in Healthy Subjects |
FDA applications (0)
No records yet.